Improved pharmaceutical nanoparticle compositions and improved methods for preparing the compositions comprising histidine-lysine copolymers and an acetate salt or phosphate anion are provided. The addition of acetate or phosphate anion to the histidine-lysine copolymer prior to mixing with a nucleic acid alters nanoparticle size and polydispersity index of the compositions and provides a more uniform particle size distribution.

Disclosed is a therapeutic patch for the gastrointestinal tract including a mucoadhesive material along with magnetic nanoparticles and a drug to be delivered to a living body, which are supported on the mucoadhesive material. A method of manufacturing the therapeutic patch for the gastrointestinal tract is also provided and includes preparing a mucoadhesive polymer, preparing a catechol precursor, mixing the mucoadhesive polymer and the catechol precursor, freeze-drying a mixture in the mixing step, mixing a powder resulting from the freeze-drying step with magnetic nanoparticles and a drug, and subjecting the resultant mixture to molding using a mold and then freeze-drying.

A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.

Compositions comprising nanoparticles are described herein. At least a portion of the nanoparticles comprises a lipid and/or polymer which is water-insoluble, and an agent incorporated in the lipid and/or polymer. The nanoparticles are optionally associated with a surface of water-soluble particles which comprise a water-soluble compound. The polymer is optionally a polyanhydride. Further described herein are processes for preparing such compositions, comprising contacting a solution comprising the lipid and/or polymer dissolved in a non-aqueous solvent with an anti-solvent (in which the lipid and/or polymer and agent are insoluble) which is miscible with the non-aqueous solvent. Further described herein are uses of the compositions for nasal administration, and devices configured for nasal administration of the composition upon atomization.

Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.

There is provided a pharmaceutical or veterinary formulation comprising: (a) a plurality of particles having a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 μm, which particles comprise solid cores coated with zinc oxide; suspended in (b) an oleaginous carrier system comprising a pharmaceutically-acceptable or veterinarily-acceptable oil, which zinc oxide coated particles comprise: (1) solid cores comprising a biologically-active agent; (2) one or more discrete layers surrounding said cores, said one or more layers each comprising at least one separate zinc oxide coating. Said zinc oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. When the cores comprise biologically-active agent, and the particles are suspended in an oleaginous carrier system, the formulation may provide for the delayed or sustained release of said active agent without a burst effect.

Provided is a process, including: extracting one or more hydrophobic active ingredients of a plant material using an extraction solvent; transferring the one or more hydrophobic active ingredients from the extraction solvent to a carrier solvent; encapsulating the one or more hydrophobic active ingredients in one or more nanoparticles; and dispersing the one or more nanoparticles in an aqueous suspension, wherein: the one or more nanoparticles have a Z-average diameter between 50 to 950 nanometers; the Z-average diameter of the one or more nanoparticles changes less than 20% when the aqueous suspension is incubated at 40° C. for four weeks; and the Z-average diameter of the one or more nanoparticles changes less than 20% when the aqueous suspension is incubated at 90° C. for 30 minutes.

Passivated semiconductor nanoparticles and methods for the fabrication and use of passivated semiconductor nanoparticles is provided herein.

The invention provides a method for validating the functioning of an apparatus with a static mixing device for mixing two liquid streams for producing nanoparticles. The static mixing device may be a jet impingement reactor. The method is based on the use of PLA, PLG or PLGA for producing polymeric nanoparticles with highly reproducible particle sizes. The invention further provides kits and liquid compositions for carrying out the method.

Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.

##STR00001##